Search the Newsreel

Ciena Corp (CIEN) Stock Down 3.2% but Still Overvalued -- GF Sco

Ciena Corp (CIEN) shares recently dropped 3.2% to $428.77, yet GuruFocus assesses the stock as significantly overvalued with a GF Value™ of $99.71. The company has a GF Score™ of 72/100, indicating above-average performance with strong financial strength and growth, but a poor valuation …

Ciena (NYSE:CIEN) Stock Price Down 3.1% - Should You Sell?

Ciena (NYSE:CIEN) shares dropped 3.1% during mid-day trading, despite strong analyst sentiment with a "Moderate Buy" consensus and an average price target of $530.56. The company recently exceeded quarterly earnings expectations, reporting EPS of $1.64 against an expected $1.46 and revenue of $1.57 billion, …

Twist Bioscience Corp (TWST) Stock Down 5.4% but Still Overvalued -- GF Score: 69/100

Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling …

Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility

Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap

An investor group comprising Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. has reported a beneficial ownership of 9.99% in Alto Neuroscience (ANRO). This ownership, totaling 4,176,711 shares, includes common stock and pre-funded warrants, with the exercise of warrants capped …

Core Scientific Completes Acquisition of Polaris DS, Advancing Planned Muskogee Expansion to 1.5 GW of Gross Power

Core Scientific has announced the completion of its acquisition of Polaris DS LLC for approximately $444 million in cash, securing about 440 MW of gross power capacity. This acquisition advances Core Scientific's plan to expand its Muskogee campus to 1.5 GW of gross power, …

Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …

Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake

ADAR1 Capital Management, LLC and Daniel Schneeberger have disclosed a 2.5% beneficial ownership stake in Spruce Biosciences, Inc. (SPRB) through a SCHEDULE 13G/A filing. This stake, totaling 67,717 shares, is held across various managed accounts, with both parties exercising shared voting and dispositive power. …

Valiant Capital discloses 5.3% Core Scientific (CORZ) position in amended 13G

Valiant Capital, along with its entities and Christopher R. Hansen, has disclosed a 5.3% beneficial ownership stake in Core Scientific (CORZ) through an amended Schedule 13G filing. This represents 16,956,009 shares of common stock, based on 321,340,441 shares outstanding as of July 23, 2026. …

Proficient Auto Logistics (PAL) Releases Q2 2026 Earnings: Revenue Declines and Loss Widens

Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors

Edwards Lifesciences Corp. (EW) stock fell 1.04% on Friday, closing at $91.60. This underperformance occurred on a generally negative trading day for the stock market, with both the S&P 500 Index and the Dow Jones Industrial Average also declining. The stock experienced its third …

Proficient Auto Logistics (PAL) widens loss and inks $130M H&A deal

Proficient Auto Logistics (PAL) reported a widened net loss of $10.4 million for the first half of 2026, compared to $4.7 million a year prior, with operating revenue slightly down to $203.1 million. Despite the loss, PAL closed a $130 million acquisition of Hansen …

TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake

Ciena (CIEN) insider files to sell 2,500 shares after recent 10b5-1 sales

An insider at Ciena Corporation (CIEN), David Rothenstein, has filed a Form 144 to sell 2,500 shares of common stock, valued at $1,106,975.00. These shares are related to Restricted Stock Units from 2021. The filing also notes previous 10b5-1 plan sales of 2,500 shares …

Ciena (CIEN) insider Marc Graff files Form 144 to sell 4,995 shares

Ciena Corporation insider Marc Graff has filed a Form 144 notice to sell 4,995 shares of common stock, valued at $2,211,736.05. These shares are related to Restricted Stock Units acquired on August 1, 2026. The filing also details previous Rule 10b5-1 sales by Graff …

Assembly Biosciences (ASMB) sees Paradigm BioCapital report 7.8% ownership stake

Paradigm BioCapital, along with its related entities and Senai Asefaw, M.D., has reported a collective beneficial ownership of 7.8% in Assembly Biosciences (ASMB), totaling 1,553,748 shares. This stake is based on an amended Schedule 13G filing, with Paradigm BioCapital International Fund Ltd. directly holding …

Twist Bioscience (TWST) director sells 2,240 shares to cover RSU tax

Twist Bioscience director Katryn Blake sold 2,240 shares of common stock on August 12, 2026, at $122.88 per share. This transaction was not a discretionary trade but was executed to cover tax liabilities arising from the vesting of Restricted Stock Units. Following the sale, …

Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap

A Schedule 13G/A filing indicates that Frazier Life Sciences-affiliated funds and individuals have updated their ownership report for Aura Biosciences (AURA). Frazier Life Sciences Public Fund, L.P. directly holds 5.6% of Aura Biosciences' common stock, and other Frazier funds also hold significant shares. The …

Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares

Vestal Point Capital, along with its Chief Investment Officer Ryan Wilder, has reported a beneficial ownership of 4.8% in Solid Biosciences Inc. (SLDB). This stake includes 4,833,796 common shares, of which 2,673,796 are issuable upon the exercise of pre-funded common stock purchase warrants. The …

Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts

Caribou Biosciences (NASDAQ:CRBU) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.75. The company's shares recently traded down 2.2% to $1.57. Caribou Biosciences reported a narrower-than-expected quarterly loss but missed revenue estimates, and institutional investors own …

Caribou Biosciences earnings beat by $0.07, revenue topped estimates

Caribou Biosciences (NASDAQ: CRBU) reported second-quarter EPS of $-0.240, beating analyst estimates by $0.07, and revenue of $2.65 million, surpassing the consensus estimate of $2.3 million. Despite the earnings beat, the company's stock price has declined by -24.770% in the last three months and …

RPG Life Sciences accepts Deepak Shukla's resignation as API head

Satellos Bioscience (MSLE) enters $50M at-the-market share deal

RPG Life Sciences completes API business transfer to subsidiary

Kingfa Science net profit up 111% in Q1FY27 to ₹802 crore

Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside

Satellos Bioscience Inc.'s average 12-month price target has been adjusted to $21.78, down from $22.04, according to estimates from 6 analysts. This new target suggests a potential upside of approximately 122% from the August 13 closing price. The consensus rating among 7 covering analysts …

Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A

Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …

Core Scientific (CORZ): Jericho Capital and Josh Resnick disclose 7.2% ownership stake

Jericho Capital Asset Management L.P. and Josh Resnick have reported a joint beneficial ownership of 22,882,942 shares of Core Scientific, Inc. common stock, which represents 7.2% of the class. They share both voting and dispositive power over these shares. This disclosure was made via …

Pentwater Capital (NASDAQ: CORZ) discloses 1.34M-share Core Scientific position

Pentwater Capital Management LP and Matthew Halbower have disclosed a beneficial ownership of 1,336,594 shares of Core Scientific, Inc. common stock, representing 0.4% of the company's outstanding shares. This includes 800,000 shares issuable upon the exercise of options. All voting and dispositive authority over …

Achieve Life Sciences (ACHV) launches $150M at-the-market stock program

Achieve Life Sciences (ACHV) has established a $150 million at-the-market (ATM) equity offering program with Jefferies LLC as the sales agent. The company plans to sell common stock periodically, with net proceeds intended for the commercialization of cytisinicline, funding a Phase 3 clinical trial …

Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise

Jeremy Hayden, an insider at Sight Sciences (SGHT), filed a Form 144 indicating his intent to sell 48,000 shares of common stock on August 14, 2026, following a stock option exercise. The planned sale has an aggregate market value of $395,878.84. This filing also …

Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing

Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …

Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 5.9% in Cellectar Biosciences (CLRB), amounting to 469,998 shares. This ownership is held through Caligan-managed funds and accounts, with shared voting and dispositive power. The percentage is based on 7,991,812 shares …

Senti Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Senti Biosciences Holdings, Inc. reported its earnings results for the second quarter and six months ended June 30, 2026. For the second quarter, the company's net loss decreased to USD 12.75 million from USD 14.73 million a year prior, with basic and diluted loss …

CORZ Stock Forecast & Analyst Ratings - August 2026

Why (ASMB) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Assembly Biosciences Inc. (ASMB), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to …